Functional and molecular interactions between ERK and CHK2 in diffuse large B-cell lymphoma

Nature Communications

Volumn 2, Issue 1, 2011, Pages

  Dai, Bojie ^a   Zhao, X Frank ^a   Mazan Mamczarz, Krystyna ^a   Hagner, Patrick ^a   Corl, Sharon ^a   Bahassi, El Mustapha ^b   Lu, Song ^a   Stambrook, Peter J ^b   Shapiro, Paul ^c   Gartenhaus, Ronald B ^a  

^a UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF CINCINNATI COLLEGE OF MEDICINE   (United States)

^c UNIVERSITY OF MARYLAND SCHOOL OF PHARMACY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CHECKPOINT KINASE 2; MITOGEN ACTIVATED PROTEIN KINASE; RAF PROTEIN; SMALL INTERFERING RNA; GLUTATHIONE TRANSFERASE; MITOGEN ACTIVATED PROTEIN KINASE 3; PROTEIN SERINE THREONINE KINASE;

ANIMAL CELL; ANIMAL CELL CULTURE; ANIMAL EXPERIMENT; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; DNA DAMAGE; DOUBLE STRANDED DNA BREAK; DRUG TARGETING; ENZYME INHIBITION; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; IN VIVO STUDY; LARGE CELL LYMPHOMA; MOLECULAR INTERACTION; MOUSE; NONHUMAN; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; PROTEIN PHOSPHORYLATION; REVIEW; TUMOR XENOGRAFT; ARTICLE; IMMUNOBLOTTING; IMMUNOPRECIPITATION; METABOLISM; MICROARRAY ANALYSIS; PHOSPHORYLATION; PHYSIOLOGY; SIGNAL TRANSDUCTION; TUMOR CELL LINE;

APOPTOSIS; CELL LINE, TUMOR; GLUTATHIONE TRANSFERASE; HUMANS; IMMUNOBLOTTING; IMMUNOPRECIPITATION; LYMPHOMA, LARGE B-CELL, DIFFUSE; MICROARRAY ANALYSIS; MITOGEN-ACTIVATED PROTEIN KINASE 3; PHOSPHORYLATION; PROTEIN-SERINE-THREONINE KINASES; SIGNAL TRANSDUCTION;

EID: 79960611506     PISSN: None     EISSN: 20411723     Source Type: Journal    
DOI: 10.1038/ncomms1404     Document Type: Review

References (29)

1. Bartek, J. & Lukas, J. Chk1 and Chk2 kinases in checkpoint control and cancer. Cancer Cell 3, 421-429 (2003). (Pubitemid 38340288)
2. Pommier, Y., Weinstein, J. N., Aladjem, M. I. & Kohn, K. W. Chk2 molecular interaction map and rationale for Chk2 inhibitors. Clin. Cancer Res. 12, 2657-2661 (2006).
3. Tan, Y., Raychaudhuri, P. & Costa, R. H. Chk2 mediates stabilization of the FoxM1 transcription factor to stimulate expression of DNA repair genes. Mol. Cell. Biol. 27, 1007-1016 (2007). (Pubitemid 46174563)
4. Lovly, C. M., Yan, L., Ryan, C. E., Takada, S. & Piwnica-Worms, H. Regulation of Chk2 ubiquitination and signaling through autophosphorylation of serine 379. Mol. Cell. Biol. 28, 5874-5885 (2008).
5. Stolz, A. et al. The CHK2-BRCA1 tumour suppressor pathway ensures chromosomal stability in human somatic cells. Nat. Cell Biol. 12, 492-499 (2010).
6. Castedo, M. et al. The cell cycle checkpoint kinase Chk2 is a negative regulator of mitotic catastrophe. Oncogene 23, 4353-4361 (2004). (Pubitemid 38850414)
7. Bell, D. W. et al. Heterozygous germ line hCHK2 mutations in Li-Fraumeni syndrome. Science 286, 2528-2531 (1999).
8. Bartkova, J. et al. Aberrations of the Chk2 tumour suppressor in advanced urinary bladder cancer. Oncogene 23, 8545-8551 (2004). (Pubitemid 39540805)
9. Perona, R., Moncho-Amor, V., Machado-Pinilla, R., Belda-Iniesta, C. & Sanchez Perez, I. Role of CHK2 in cancer development. Clin. Transl. Oncol. 10, 538-542 (2008).
10. Antoni, L., Sodha, N., Collins, I. & Garrett, M. D. CHK2 kinase: cancer susceptibility and cancer therapy-two sides of the same coin? Nat. Rev. Cancer 7, 925-936 (2007). (Pubitemid 350165855)
11. DiTullio, R. A. Jr. et al. 53BP1 functions in an ATM-dependent checkpoint pathway that is constitutively activated in human cancer. Nat. Cell Biol. 4, 998-1002 (2002). (Pubitemid 35469432)
12. Ghosh, J. C., Dohi, T., Raskett, C. M., Kowalik, T. F. & Altieri, D. C. Activated checkpoint kinase 2 provides a survival signal for tumor cells. Cancer Res. 66, 11576-11579 (2006). (Pubitemid 46094165)
13. Golding, S. E. et al. Extracellular signal-related kinase positively regulates ataxia telangiectasia mutated, homologous recombination repair, and the DNA damage response. Cancer Res. 67, 1046-1053 (2007).
14. Dai, B. et al. Extracellular signal-regulated kinase positively regulates the oncogenic activity of MCT-1 in diffuse large B-cell lymphoma. Cancer Res. 69, 7835-7843 (2009).
15. Dai, Y. et al. Interruption of the Ras/MEK/ERK signaling cascade enhances Chk1 inhibitor-induced DNA damage in vitro and in vivo in human multiple myeloma cells. Blood 112, 2439-2449 (2008).
16. Dai, Y. et al. Pharmacological inhibitors of the mitogen-activated protein kinase (MAPK) kinase/MAPK cascade interact synergistically with UCN-01 to induce mitochondrial dysfunction and apoptosis in human leukemia cells. Cancer Res. 61, 5106-5115 (2001). (Pubitemid 32681542)
17. Hans, C. P. et al. Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray. Blood 103, 275-282 (2004). (Pubitemid 38029949)
18. Nyman, H., Jerkeman, M., Karjalainen-Lindsberg, M. L., Banham, A. H. & Leppa, S. Prognostic impact of activated B-cell focused classification in diffuse large B-cell lymphoma patients treated with R-CHOP. Mod. Pathol. 22, 1094-1101 (2009).
19. Yu, Q., Rose, J. H., Zhang, H. & Pommier, Y. Antisense inhibition of Chk2/ hCds1 expression attenuates DNA damage-induced S and G2 checkpoints and enhances apoptotic activity in HEK-293 cells. FEBS Lett. 505, 7-12 (2001). (Pubitemid 32831020)
20. Arienti, K. L. et al. Checkpoint kinase inhibitors: SAR and radioprotective properties of a series of 2-arylbenzimidazoles. J. Med. Chem. 48, 1873-1885 (2005). (Pubitemid 40396318)
21. Bartek, J., Falck, J. & Lukas, J. CHK2 kinase-a busy messenger. Nat. Rev. Mol. Cell Biol. 2, 877-886 (2001).
22. Yeh, Y. H., Huang, Y. F., Lin, T. Y. & Shieh, S. Y. The cell cycle checkpoint kinase CHK2 mediates DNA damage-induced stabilization of TTK/hMps1. Oncogene 28, 1366-1378 (2009).
23. Durocher, D. & Jackson, S. P. DNA-PK, ATM and ATR as sensors of DNA damage: variations on a theme? Curr. Opin. Cell Biol. 13, 225-231 (2001). (Pubitemid 32209224)
24. Stevens, C., Smith, L. & La Thangue, N. B. Chk2 activates E2F-1 in response to DNA damage. Nat. Cell Biol. 5, 401-409 (2003). (Pubitemid 36592262)
25. Matsuoka, S. et al. Ataxia telangiectasia-mutated phosphorylates Chk2 in vivo and in vitro. Proc. Natl Acad. Sci. USA 97, 10389-10394 (2000).
26. Tort, F. et al. CHK2-decreased protein expression and infrequent genetic alterations mainly occur in aggressive types of non-Hodgkin lymphomas. Blood 100, 4602-4608 (2002). (Pubitemid 35429704)
27. Nyati, M. K. et al. Ataxia telangiectasia mutated down-regulates phosphoextracellular signal-regulated kinase 1/2 via activation of MKP-1 in response to radiation. Cancer Res. 66, 11554-11559 (2006). (Pubitemid 46094161)
28. Cerchietti, L. C. et al. A purine scaffold Hsp90 inhibitor destabilizes BCL-6 and has specific antitumor activity in BCL-6-dependent B cell lymphomas. Nat. Med. 15, 1369-1376 (2009).
29. Shapiro, P. S. et al. Extracellular signal-regulated kinase activates topoisomerase IIalpha through a mechanism independent of phosphorylation. Mol. Cell Biol. 19, 3551-3560 (1999). (Pubitemid 29193814)